Pharsight

Ironwood Pharms Inc patents expiration

1. Duzallo patents expiration

DUZALLO's oppositions filed in EPO
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(1 year, 2 months from now)

US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Apr, 2029

(4 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Aug, 2029

(5 years from now)

US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Dec, 2029

(5 years from now)

US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia
Aug, 2031

(7 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Dec, 2031

(7 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

Family Patents

2. Zurampic patents expiration

ZURAMPIC's oppositions filed in EPO
Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(1 year, 2 months from now)

US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Apr, 2029

(4 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Aug, 2029

(5 years from now)

US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Dec, 2029

(5 years from now)

US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia
Aug, 2031

(7 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Dec, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2020

Drugs and Companies using LESINURAD ingredient

NCE-1 date: 23 December, 2019

Market Authorisation Date: 22 December, 2015

Treatment: Treatment of gout; Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone; Treatment of hyperuricemia; ...

Dosage: TABLET;ORAL

More Information on Dosage

ZURAMPIC family patents

Family Patents